Thyrocare

Tests you can trust

November 06, 2026

To,

National Stock Exchange of India Limited	BSE Limited
Exchange Plaza	Phiroze Jeejeebhoy Towers
Bandra Kurla Complex,	Dalal Street,
Bandra (E), Mumbai - 400051	Mumbai- 400001
(SYMBOL: THYROCARE)	**(SCRIP CODE: 539871)**

Sub : **Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI LODR Regulations**"), we wish to inform you that Dr. Preet Kaur, Chief Scientific Officer and part of the Senior Management Personnel of Thyrocare Technologies Limited ("**the Company**"), has decided to pursue an opportunity outside the organization. She will complete her handover and cease to be associated with the Company with effect from November 06, 2026. We place on record our appreciation for her valuable contributions and wish her the very best in her future endeavors.

The Company has substantially progressed the process of identifying a suitable replacement for the said position. The details will be intimated to the Stock Exchanges in due course, in compliance with applicable laws.

In compliance with Regulation 30 of the SEBI LODR Regulations read with **SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**, the requisite disclosure is enclosed as **Annexure-I**. The resignation letter submitted by Dr. Preet Kaur is enclosed as **Annexure-II.**

The aforesaid disclosures are also being made available on the website of the Company at **https://investor.thyrocare.com/announcements/**.

This is submitted for your information and records.

Yours faithfully,
For **Thyrocare Technologies Limited**

Brijesh Kumar

Digitally signed by Brijesh Kumar
Date: 2026.11.06 16:15:38 +05'30'

Brijesh Kumar
Company Secretary and Compliance Officer

Encl: A/a

Thyrocare
Tests you can trust

Annexure-I

Disclosure under sub-para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Change in Senior Management Personnel

1.	Name & Designation	Dr. Preet Kaur – Chief Scientific Officer
2.	Reason for change viz. ~~appointment~~, ~~re-appointment,~~ resignation~~, removal, death or otherwise~~	Resignation
3.	Date of ~~appointment/re appointment/~~ cessation~~ (as applicable) &~~ ~~term of appointment/re-appointment;~~	With effect from November 06, 2026
4.	Brief Profile (in case of appointment)	Not Applicable
5.	Disclosure of relationships between directors (in case of appointment of a Director)	Not Applicable

Annexure-II

To
Dr. Ramesh Kinha
Chief Operating Officer
Thyrocare Technologies Limited

Subject: Formal Resignation – Chief Scientific Officer

Dear Dr. Kinha,

Please accept this letter as my formal resignation from the position of Chief Scientific Officer at Thyrocare Technologies Limited, with effect from October 8, 2026.

I am resigning to pursue a better career opportunity.


I would like to express my sincere gratitude for the opportunities, guidance and support extended to me during my tenure with the organization.

In accordance with my notice period, I request you to consider November 6, 2026, as my last working day.

I remain committed to ensuring a smooth transition and will extend my full support in completing the necessary handover of responsibilities before my departure.

Thank you once again for the association and experience.

Regards,



Dr. Preet Kaur
Employee ID: 4326E